about
Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.Significant changes in the composition of the precursor B-cell compartment in children less than 2 years old.Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.Impairment of Immune Function in Children with Familial Hemophagocytic Lymphohistiocytosis.Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis.Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.Incidence of Infectious Complications in Children With Acute Lymphoblastic Leukemia Treated With Hematopoietic Stem Cell Transplantation.Transplant-related mortality and survival in children with malignancies treated with allogeneic hematopoietic stem cell transplantation. A multicenter analysis.Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Usefulness of Post-Transplant Hematopoietic Chimera Monitoring by Use of the Quantitative Fluorescence Polymerase Chain Reaction Method.Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.Internal hemipelvectomy in the management of pelvic Ewing sarcoma - are outcomes better than with radiation therapy?Management and follow-up of Ewing sarcoma patients with isolated lung metastases.Ovarian function in female survivors after multimodal Ewing sarcoma therapy.Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.Prediction of Ewing Sarcoma treatment outcome using attenuated tissue reflection FTIR tissue spectroscopyPredicting Ewing Sarcoma Treatment Outcome Using Infrared Spectroscopy and Machine LearningNeurologic complications in children after hemaopoietic stem cell transplantation: a single-center experienceOutcome of Ewing sarcoma in children and adolescents with Ewing sarcoma: a five-year survival from a single institutionDonor origin of Graves disease in a BMT recipient: evidence from FISH studies of thyroid tissueCCR5 gene polymorphism affects the risk of GvHD after haematopoietic stem cell transplantation from an unrelated donorValidation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology groupHLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donorDevelopment and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology andClinical characteristics and analysis of treatment result in children with Ph-positive acute lymphoblastic leukaemia in Poland between 2005 and 2017Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignanciesImpact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation
P50
Q38845467-54CF50E7-8EAF-456E-8443-B98483ACB942Q39454415-A254032C-B6BB-4BCD-9225-3B781753B72DQ40650204-D6384D92-6143-41CE-8E3D-A2A6A8FF6EBEQ40751502-BD02A4D4-934D-448E-BF6D-556E9FF44A72Q41030597-BE34EEE8-5221-404E-87BA-3E6C694331BEQ41053811-51A885F2-F14F-4A1B-BB79-781E94E500E2Q41532474-2AFF5F03-3787-43B6-BDAB-22746F4CFA98Q41732815-6CEDA552-C6A1-48A6-BDD3-D3CB027EB121Q42248606-7E93C461-6B06-4270-B8DD-2F0225EC44CDQ46812391-00729443-51CB-461F-97A2-5E4FB70D2180Q47576492-3E8DE50A-B074-4A5D-92A0-D2449F8F357AQ48111168-E9EAD5C7-4CB4-4185-A135-3D4894C102AFQ48846219-1EB4DAC5-E784-446C-9F62-67376D9C6E39Q50037007-6D7A21B0-EBAA-457F-8AE2-C96F12A1043EQ50079472-A88F8274-58C7-4324-85C4-5DE9D9E3C3DDQ50420224-8C83B02B-E223-4CCD-A7A9-7AC8172F94CDQ50848517-225DBBC8-513D-4982-A224-A23B27A49CDDQ50856165-15751936-0760-4C91-9C93-8E295D0E16B5Q51061203-C3073EF4-BCAB-4E23-A070-522A55F8E9A5Q53167841-EE20BF99-0428-4F37-A1FD-CE70A3705EB2Q58770905-F120ABD0-6165-471D-B22A-D170FCC98F8AQ64077124-10A97499-BF15-4224-8E7F-7429C6090E8CQ79899579-960C1F3D-6997-48DB-8DFD-FDD7EB3B412CQ81214825-0AAF30EE-6553-43AC-BA44-6AD1F64CBF45Q82735560-190370FC-E2A3-449F-89FF-592B9C0C8A11Q87020433-60DCCD19-0B77-4FB3-B331-CAA4DE538B7AQ87673567-35C1F05A-14A1-43B6-8D5C-8DDA1B036E6CQ88236777-5E97BB0B-71D7-4CB8-A9C0-9C072E0D2F15Q89029268-081C6262-DA44-40FC-93C4-DB238DE4C1C6Q90196782-6B0D1598-EE86-422A-989B-CFC6AF6B571EQ90590399-880F7745-4170-45F6-AC3E-4F5CD13704CDQ91470648-7D279DE4-92F9-4D12-B8F0-0A6B5FCEC957
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7094-9129
@en
name
Katarzyna Drabko
@ast
Katarzyna Drabko
@en
Katarzyna Drabko
@es
Katarzyna Drabko
@nl
type
label
Katarzyna Drabko
@ast
Katarzyna Drabko
@en
Katarzyna Drabko
@es
Katarzyna Drabko
@nl
prefLabel
Katarzyna Drabko
@ast
Katarzyna Drabko
@en
Katarzyna Drabko
@es
Katarzyna Drabko
@nl
P214
P106
P1153
8324888700
P214
P31
P496
0000-0002-7094-9129
P7859
viaf-302529003